Marc Goldberg, MD
Ophthalmology · Tulsa, OKNPI 1952396186
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations.
Across 120 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$947
- Mallinckrodt Hospital Products Inc.$631
- Alcon$457
- Bausch & Lomb Americas Inc.$425
- Dompe US, Inc.$307
- Sun Pharmaceutical Industries Inc.$227
- plus $960 from 14 others
What the payments were for
- Food & beverage$3,84297%
- Education$932%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 21 | $947 |
| Mallinckrodt Hospital Products Inc. | 21 | $631 |
| Alcon | 11 | $457 |
| Bausch & Lomb Americas Inc. | 13 | $425 |
| Dompe US, Inc. | 6 | $307 |
| Sun Pharmaceutical Industries Inc. | 12 | $227 |
| The Cameron-ehlen Group, Inc. | 2 | $142 |
| Shire North American Group Inc | 1 | $122 |
| Aerie Pharmaceuticals, Inc. | 6 | $111 |
| AbbVie(2 entities) | 5 | $111 |
| NEW World Medical,inc. | 1 | $99 |
| Rxsight Inc | 4 | $85 |
| Harrow Eye, LLC | 3 | $67 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $65 |
| Oyster Point Pharma, Inc. | 4 | $61 |
| Tarsus Pharmaceuticals, Inc. | 2 | $39 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Novartis | 1 | $11 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$360
- enVista MX60 IOL$240
- Oxervate$237
- XIIDRA$228
- KXL System$176
- Photrexa$176
- AcrySof IQ PanOptix UV IOL$146
- AcrySof IQ VIVITY$146
- iDose$136
- iStent infinite Trabecular Micro-Bypass System Model iS3$135
- Hydrus Microstent$126
- Voyager DSLT$126
- enVista Aspire IOL$120
- HEALON PRO$120
- Tecnis Simplicity$120
- MIEBO$106
How this compares
$3,954 in reported general payments places this provider in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 15 | $686,409 |
| RestasisCyclosporine | 33 | $28,600 |
| Prednisolone Acetate | 669 | $26,681 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,648 |
| RhopressaNetarsudil Mesylate | 27 | $11,191 |
| MoxifloxacinMoxifloxacin Hcl | 199 | $5,686 |
| Fluorometholone | 89 | $5,432 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $5,201 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 29 | $4,345 |
| LumiganBimatoprost | 13 | $3,773 |
| Lotemax SmLoteprednol Etabonate | 15 | $3,694 |
| Ketorolac Tromethamine | 136 | $2,918 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,684 |
| ValacyclovirValacyclovir Hcl | 44 | $2,452 |
| Acyclovir | 136 | $2,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $631 | $686,40915 claims |
| AbbVieRestasis, Combigan, Lumigan | $111 | $37,57360 claims |
| Bausch & Lomb Americas Inc.Miebo | $425 | $18,64825 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $111 | $11,19127 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $65 | $5,84932 claims |
| AlconSimbrinza | $457 | $2,68412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Tulsa
- Shehzad BatliwalaTulsa$11K
- Thomas FinleyTulsa$9K
- Jamal SiddiquiTulsa$7K
- Kelli DyerTulsa$6K
- Lars FreisbergTulsa$6K
- Neha SangalTulsa$5K
- Thomas BriggsTulsa$4K
- Daniel LangleyTulsa$3K
- Mark AllisonTulsa$3K
- Justin ParschauerTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.